2CBB6A30-1BF8-4F58-A2C1-99AFA8685277
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 146.02496714848883
- age_years
- 27
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.529
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.402
- PROTEIN_SECRETION+0.304
- HEDGEHOG_SIGNALING+0.265
- PI3K_AKT_MTOR_SIGNALING+0.250
- MITOTIC_SPINDLE+0.244
- MTORC1_SIGNALING+0.244
- UV_RESPONSE_UP+0.238
- UV_RESPONSE_DN+0.234
- ADIPOGENESIS+0.205
Top 10 suppressed
- ANGIOGENESIS-0.396
- IL6_JAK_STAT3_SIGNALING-0.351
- INTERFERON_ALPHA_RESPONSE-0.335
- INTERFERON_GAMMA_RESPONSE-0.316
- TNFA_SIGNALING_VIA_NFKB-0.304
- ALLOGRAFT_REJECTION-0.283
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.263
- COAGULATION-0.200
- E2F_TARGETS-0.194
- IL2_STAT5_SIGNALING-0.185
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 02F669D8-FB9F-45AF-A999-5886E5C2DAF0 | — | — | 0.945 |
| 2 | FD166A94-332D-426D-9E36-E4272F3772FC | — | — | 0.932 |
| 3 | 864D2BA3-EB33-4DC2-A228-4CADDCF526D4 | — | — | 0.924 |
| 4 | 5085CE66-190D-478B-9AB6-55AE71C41CCF | — | — | 0.901 |
| 5 | 3DC38276-A6D2-49C6-8F54-3F50F6BFAD0C | — | — | 0.890 |
| 6 | 28E176DE-49DB-4F39-B022-C89235590CAC | — | — | 0.880 |
| 7 | D155B4CA-927F-4B4F-B6BC-2D41267F195E | — | — | 0.858 |
| 8 | C4100609-0651-40E1-997A-0059432736B3 | — | — | 0.857 |
| 9 | 1E2D87A6-48B8-47FA-A801-AFEA7E01E829 | — | — | 0.854 |
| 10 | SRR934831 | — | — | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.529 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.402 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.304 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.265 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.244 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.244 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.238 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.234 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.205 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.166 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.127 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.124 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.121 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.102 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.096 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.092 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.088 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.078 | Temsirolimus | — uncovered |